Autoimmune screening panel in patients with multiple sclerosis: A Vienna multiple sclerosis database study
European Journal of Neurology · 2025
DOI: 10.1111/ene.16558 ↗At a glance
Journal article in European Journal of Neurology, 2025. Written by Fabian Föttinger and 13 co-authors. Institution: Department of Neurology, Medical University of Vienna, Vienna, Austria. Major MEDLINE topics: Multiple Sclerosis, Databases, Factual. Cited 2 times so far (Crossref); 33 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Austrian MS Research Society.
Abstract (original language)
Background and purpose Autoimmune screening panels (ASPs) are often ordered as a part of the diagnostic workup in people with suspected multiple sclerosis (MS). However, data on the significance of ASP seropositivity in MS are scarce. This study aimed to investigate whether routine implementation of ASPs is viable in MS diagnostic workup.
Methods
In this retrospective study, we included patients from the Vienna Multiple Sclerosis Database who were diagnosed with MS according to current McDonald criteria between 2014 and 2021 and had an ASP performed.
Results
We analyzed 212 patients (mean age at serology = 30.4 [SD = 8.5] years, 67% female). Red flag symptoms for presence of systemic autoimmune disease were reported by 5.6% of patients during initial evaluation (sicca syndrome [ n = 5], joint pain [ n = 4], dermatitis [ n = 4]). Complement levels (C3c and C4) were below the lower reference level in 26 of 134 (19.4%) and three of 134 (2.2%), respectively. Antinuclear antibodies (ANAs) were positive in 24 of 210 (11.4%), with 18 (8.6%), five (2.4%), and one (0.5%) having mildly, moderately, and strongly positive ANA titers. Extractable nuclear antibody subsets were positive in 10 of 211 (4.7%) patients. ASPs led to the diagnosis of mixed connective tissue disease ( n = 1), psoriatic arthritis ( n = 1), and Sjögren syndrome ( n = 2; positive predictive value [PPV] = 4.9%, negative predictive value [NPV] = 99.3%). Among patients presenting with red flag symptoms, ASPs had better overall test performance (PPV = 100%, NPV = 88.9%).
Conclusions
The rate of ASP seropositivity in MS is low and within the range of the general population. Performance of ASPs without clinical suspicion of systemic autoimmune disease seems unwarranted.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Neurology, Medical University of Vienna, Vienna, Austria.
- Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Vienna, Austria.
ORCID profiles: Fabian Föttinger, Paulus Rommer, Barbara Kornek, Stefan Macher, Tobias Zrzavy, Gabriel Bsteh
Funding
- Austrian MS Research Society
Cite
APA
Föttinger, F., Krajnc, N., Riedl, K., Leutmezer, F., Ponleitner, M., Rommer, P., Kornek, B., Macher, S., Schmied, C., Zebenholzer, K., Zulehner, G., Zrzavy, T., Berger, T., & Bsteh, G. (2025). Autoimmune screening panel in patients with multiple sclerosis: A Vienna multiple sclerosis database study. European Journal of Neurology. https://doi.org/10.1111/ene.16558
Vancouver
Föttinger F, Krajnc N, Riedl K, Leutmezer F, Ponleitner M, Rommer P, et al. Autoimmune screening panel in patients with multiple sclerosis: A Vienna multiple sclerosis database study. European Journal of Neurology. 2025. doi:10.1111/ene.16558
BibTeX
@article{Fttinger2025,
author = {Föttinger, Fabian and Krajnc, Nik and Riedl, Katharina and Leutmezer, Fritz and Ponleitner, Markus and Rommer, Paulus and Kornek, Barbara and Macher, Stefan and Schmied, Christiane and Zebenholzer, Karin and Zulehner, Gudrun and Zrzavy, Tobias and Berger, Thomas and Bsteh, Gabriel},
title = {Autoimmune screening panel in patients with multiple sclerosis: A Vienna multiple sclerosis database study},
journal = {European Journal of Neurology},
year = {2025},
doi = {10.1111/ene.16558}
}
EUVIMED